Ahmed R Ali

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Amyotrophic Lateral Sclerosis

Molecular Docking

Epidermal Growth Factor Receptor

Top Venues

Drug development research

This page only lists publications with an associated author ORCID identifier.

Publications

Samar S Tawfik, Abdelrahman Hamdi, Ahmed R Ali, Abdullah A Elgazar, Hamed W El-Shafey, Adel S El-Azab, Ahmed H Bakheit, Mohamed M Hefnawy, Hazem A Ghabour, Alaa A-M Abdel-Aziz
S -Alkylated quinazolin-4(3 H )-ones as dual EGFR/VEGFR-2 kinases inhibitors: design, synthesis, anticancer evaluation and docking study. RSC advances 14 (36) (2024)
Samar S Tawfik, Abdelrahman Hamdi, Ahmed R Ali, Abdullah A Elgazar, Hamed W El-Shafey, Adel S El-Azab, Ahmed H Bakheit, Mohamed M Hefnawy, Hazem A Ghabour, Alaa A-M Abdel-Aziz
S -Alkylated quinazolin-4(3 H )-ones as dual EGFR/VEGFR-2 kinases inhibitors: design, synthesis, anticancer evaluation and docking study. RSC advances 14 (36) (2024)
Abdullah Haikal, Ahmed R Ali
Chemical composition and toxicity studies on Lantana camara L. flower essential oil and its in silico binding and pharmacokinetics to superoxide dismutase 1 for amyotrophic lateral sclerosis (ALS) therapy. RSC advances 14 (33) (2024)
Abdullah Haikal, Ahmed R Ali
Chemical composition and toxicity studies on Lantana camara L. flower essential oil and its in silico binding and pharmacokinetics to superoxide dismutase 1 for amyotrophic lateral sclerosis (ALS) therapy. RSC advances 14 (33) (2024)
Alaa A Abd Elhameed, Ahmed R Ali, Hazem A Ghabbour, Said M Bayomi, Nadia S El-Gohary
Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2. Drug development research (2023)
Ahmed Elbermawi, Ahmed R Ali, Yhiya Amen, Ahmed Ashour, Kadria F Ahmad, El-Sayed S Mansour, Ahmed F Halim
Anti-diabetic activities of phenolic compounds of Alternaria sp., an endophyte isolated from the leaves of desert plants growing in Egypt. RSC advances 12 (38) (2022)